• Discuss strategies for trial design that account for hormonal fluctuations, comorbidities, and age-related variables unique to the menopausal transition.
• Highlight regulatory, industry, and advocacy efforts that are pushing for menopause-specific representation in therapeutic areas beyond just women’s health.
• Sharing advancements to educate clinical trial patients about menopause.

• Understanding the payer mindset, what is valuable in women’s healthcare innovation. 

• Defining clinical outcomes, cost containment, and population impact.

• Determining Evidence for Adoption & Reimbursement, what is ‘gold standard data’.

• Case examples of evidence that moved the needle, RWE, and how to avoid common mistakes

• Exploring the current landscape of screening services in women’s cancers and market opportunities to address unmet need.

• Sharing how AI, technology, and genetic testing can address gaps in access.

• How providers and patients can be equipped with tools for early detection and cancer prevention.

• How the demand for menopause-focused functional foods, probiotics, and supplements is shaping new business opportunities.
• Sharing insights into how nutrition and food as medicine links bone, heart, and brain health in menopause and the opportunity to address these health outcomes through wellness.
• Expanding access to menopause nutrition solutions through pharmacies, e-commerce, consumer wellness, and employer plans.

Demonstrate how AI-driven initiatives - like predictive modelling and automated inspection -translate into measurable outcomes (e.g., defect reduction, shorter batch release cycles) that justify capital investment and cross-functional prioritization

• Leveraging tech and epidemiological data to reduce diagnostic delays in reproductive health.
• Exploring AI, biomarkers, digital therapeutics, and digital platforms that enable earlier and more accurate diagnoses.
• Advice to start-ups and sharing the market opportunity for clinical integration in preventative & diagnostic women’s health.